Detection of B cell lymphoma 2, tumor protein 53, and FAS gene transcripts in blood cells of patients with breast cancer

Indian Journal of Cancer

Volumn 47, Issue 4, 2010, Pages 412-417

  Jaberipour, M ^a   Habibagahi, M ^b   Hosseini, A ^a   Abbasi, M ^a   Sobhani Lari, A ^a   Talei, A ^a,c   Ghaderi, A ^a,d  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Department of Immunology   (Ireland)

^c Department of Surgery ^*  (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

BCL 2; breast cancer; FAS; TP53

Indexed keywords

FAS LIGAND; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BLOOD SAMPLING; BREAST CANCER; CANCER INHIBITION; CANCER STAGING; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTOLOGY; HUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; UPREGULATION;

ANTIGENS, CD95; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650113414     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.73576     Document Type: Article

References (38)

1. Bebenek M, Dus D, Kozlak J. FAS/FAS-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. Anticancer Res 2007;27:215-8.
2. Kawakami A, Eguchi K. Involvement of apoptotic cell death in autoimmune diseases. Med Electron Microsc 2002;35:1-8.
3. Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, et al. FAS signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006;12:3705-12.
4. Bewick M, Conlon M, Parissenti AM, Lee H, Zhang L, Gluck S, et al. Soluble FAS (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J Hematother Stem Cell Res 2001;10:759-68.
5. Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28:1067-73.
6. Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003;13:115-23.
7. Thomadaki H, Scorilas A. Molecular profile of the BCL-2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Connect Tissue Res 2008;49:261-4.
8. Kyndi M, Sorensen FB, Knudsen H, Alsner J, Overgaard M, Nielsen HM, et al. Impact of BCL-2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer: A subgroup analysis of DBCG82 b&c. Acta Oncol 2008;47:608-17.
9. Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL-2 is an independent prognostic marker in breast cancer. BMC Cancer 2008;8:153.
10. Yang Q, Moran MS, Haffty BG. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat 2009;115:343-8.
11. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
12. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
13. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998;52:79-98.
14. Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, et al. Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53. Ann Surg 2001;233:630-8.
15. Jansen RL, Joosten-Achjanie SR, Volovics A, Arends JW, Hupperets PS, Hillen HF, et al. Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer. Anticancer Res 1998;18:4455-62.
16. Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 2009;39:217-24.
17. Di GH, Liu G, Wu J, Shen ZZ, Shao ZM. [Peripheral blood mutated p53 DNA and its clinical value in human breast cancer]. Zhonghua Zhong Liu Za Zhi 2003;25:137-40.
18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
19. Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: Recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009;100:1627-37.
20. Martin M, Garcia-Saenz JA, Maestro De las Casas ML, Vidaurreta M, Puente J, Veganzones S, et al. Circulating tumor cells in metastatic breast cancer: Timing of blood extraction for analysis. Anticancer Res 2009;29:4185-7.
21. Schmitt M, Foekens JA. Circulating tumor cells in blood of primary breast cancer patients assessed by a novel RT-PCR test kit and comparison with status of bone marrow-disseminated tumor cells. Breast Cancer Res 2009;11:109.
22. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
23. Yakirevich E, Maroun L, Cohen O, Izhak OB, Rennert G, Resnick MB. Apoptosis, proliferation, and FAS (APO-1, CD95)/FAS ligand expression in medullary carcinoma of the breast. J Pathol 2000;192:166-73.
24. Bi Y, Wei L, Mao HT, Zhang L, Zuo WS. [Expressions of FAS, CTLA-4 and RhoBTB2 genes in breast carcinoma and their relationship with clinicopathological factors]. Zhonghua Zhong Liu Za Zhi 2008;30:749-53.
25. Bebenek M, Dus D, Kozlak J. FAS and FAS ligand as prognostic factors in human breast carcinoma. Med Sci Monit 2006;12:CR457-61.
26. Sjostrom-Mattson J, von Boguslawski K, Bengtsson NO, Mjaaland I, Salmenkivi K, Blomqvist C. The expression of p53, bcl-2, bax, FAS and FASL in the primary tumour and lymph node metastases of breast cancer. Acta Oncol 2009;1-7. In press
27. Puiu L, Petrakou E, Apostolidou A, Athanassiadou A, Psiouri L, Papachatzopoulou A, et al. Lack of FAS (APO-1/CD95) gene structural alterations or transcript variant ratio changes in breast cancer. Cancer Lett 2003;194:91-7.
28. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
29. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth by BCL-2. Cancer Res 1994;54:3714-7.
30. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006;12:2468-75.
31. Yang Q, Moran MS, Haffty BG. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat 2009;115:343-8.
32. Vargas-Roig LM, Cuello-Carrion FD, Fernandez-Escobar N, Daguerre P, Leuzzi M, Ibarra J, et al. Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Mol Oncol 2008;2:102-11.
33. Alireza A, Raheleh S, Abbass R, Mojgan M, Mohamadreza M, Gholamreza M, et al. An immunohistochemistry study of tissue bcl-2 expression and its serum levels in breast cancer patients. Ann N Y Acad Sci 2008;1138:114-20.
34. Kiaris H, Chatzistamou I, Trimis G, Frangou-Plemmenou M, Pafiti-Kondi A, Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 2005;65:1627-30.
35. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer 1999;80:1968-73.
36. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004;6:R24-30.
37. Gerson R, Alban F, Villalobos A, Serrano A. [Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype]. Gac Med Mex 2008;144:27-34.
38. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006;13:293-325.